Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication.
Participants who completed up to week 190 in the long-term weight control study were monitored after cessation of medication between weeks 190 and 210. Caloric restriction, behavior modification sessions, exercise reinforcement, and physician visits continued. We assessed whether or not participants had reset their weight control mechanisms and compared the effect of stopping medication under open-label conditions (weeks 190 to 210) with the results of stopping anorexiants under double-blind conditions (weeks 160 to 190). At week 210, participants were, on average, 1.4 +/- 1.0 kg (mean +/- SEM, 1.5% +/- 1.1%) below their weights at baseline (week 0). Of the 48 participants who remained in the study, 13 were still 5% or more and seven were 10% or more below their initial weights. On average, participants gained 2.7 +/- 0.5 kg (3.2%) in the period from weeks 190 to 210. Those who had been taking medication in the period from weeks 160 to 190 gained weight at a somewhat faster rate than those who had been taking placebo. However, participants who had transferred from fenfluramine plus phentermine to no medication in this phase gained at a slower rate than participants who had changed from fenfluramine plus phentermine to placebo under double-blind conditions at week 160 (0.195 kg per week versus 0.277 kg per week). The findings indicate that participants had difficulty maintaining weight loss without anorexiant medications. Despite long periods of time at weights much lower than baseline, permanent resetting of weight control mechanisms could not be shown for most participants.
Weintraub
M
M
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, NY.
Sundaresan
P R
PR
Schuster
B
B
Averbuch
M
M
Stein
E C
EC
Byrne
L
L
D000328:Adult; D001521:Behavior Therapy; D001835:Body Weight; D004038:Diet, Reducing; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015444:Exercise; D005260:Female; D005277:Fenfluramine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000628:therapy*; D010645:Phentermine / Q000009:adverse effects / Q000627:therapeutic use*; D015430:Weight Gain
D005277:Fenfluramine; D010645:Phentermine